売上高・売上総利益率の推移
| 年度 |
売上高 |
売上総利益率 |
| 2020/12 |
0 |
- |
| 2019/12 |
21,000 |
- |
| 2018/12 |
138,000 |
- |
| 2017/12 |
15,000 |
- |
| 2016/12 |
19,000 |
- |
| 2013/12 |
399,000 |
|
| 2012/12 |
97,000 |
|
営業利益・営業利益率の推移
| 年度 |
営業利益 |
営業利益率 |
| 2024/12 |
-7,387 |
- |
| 2023/12 |
-10,824 |
- |
| 2022/12 |
-11,462 |
- |
| 2021/12 |
-13,511 |
- |
| 2020/12 |
-8,793 |
- |
| 2019/12 |
-8,987 |
|
| 2018/12 |
-7,364 |
|
| 2017/12 |
-14,062 |
|
| 2016/12 |
-9,015 |
|
| 2015/12 |
-10,237 |
|
| 2014/12 |
-8,826 |
|
| 2013/12 |
-20,949 |
|
| 2012/12 |
-12,975 |
|
|
(単位:%)
|
2012/12
|
2013/12
|
2014/12
|
2015/12
|
2016/12
|
2017/12
|
2018/12
|
2019/12
|
2020/12
|
2021/12
|
2022/12
|
2023/12
|
2024/12
|
|
売上高
|
97
|
399
|
-
|
-
|
19
|
15
|
138
|
21
|
0
|
-
|
-
|
-
|
-
|
|
売上成長率(%)
|
-
|
|
-
|
-
|
-
|
|
|
|
-
|
-
|
-
|
-
|
-
|
|
研究開発費
|
56,182
|
17,651
|
5,680
|
6,925
|
5,415
|
5,370
|
4,326
|
4,300
|
4,431
|
8,886
|
7,012
|
6,332
|
3,643
|
|
営業費用
|
-
|
21,348
|
8,897
|
10,271
|
9,034
|
14,077
|
7,502
|
9,008
|
8,793
|
13,511
|
11,462
|
10,824
|
7,387
|
|
営業利益
|
-12,975
|
-20,949
|
-8,826
|
-10,237
|
-9,015
|
-14,062
|
-7,364
|
-8,987
|
-8,793
|
-13,511
|
-11,462
|
-10,824
|
-7,387
|
|
営業利益率 (%)
|
|
|
-
|
-
|
|
|
|
|
-
|
-
|
-
|
-
|
-
|
|
経常(税引前)利益
|
-12,880
|
-20,925
|
-8,800
|
-10,223
|
-8,994
|
-14,073
|
-7,360
|
-8,908
|
-8,794
|
-13,287
|
-11,480
|
-
|
-
|
|
経常(税引前)利益率(%)
|
-13278.4
|
-5244.4
|
-
|
-
|
-47336.8
|
-93820
|
-5333.3
|
-42419.0
|
-
|
-
|
-
|
-
|
-
|
|
法人税等合計
|
-
|
-
|
0
|
0
|
0
|
-1,621
|
0
|
0
|
0
|
-
|
-
|
-
|
-
|
|
実効税率(%)
|
-
|
-
|
|
|
|
|
|
|
0.0
|
-
|
-
|
-
|
-
|
|
純利益
|
-12,880
|
-20,925
|
-8,800
|
-10,223
|
-8,994
|
-12,452
|
-7,360
|
-8,908
|
-8,794
|
-13,287
|
-11,480
|
-10,826
|
-7,150
|
|
純利益率(%)
|
|
|
-
|
-
|
|
|
|
|
-
|
-
|
-
|
-
|
-
|
|
一株あたり利益
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-10.1
|
-
|
-9.08
|
|
希薄化後一株あたり利益
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-10.1
|
-
|
-9.08
|
|
EBITDA
|
|
|
|
|
|
|
|
|
-8,721
|
-13,436
|
-11,391
|
-10,768
|
-7,385
|
|
EBITDAマージン(%)
|
|
|
-
|
-
|
|
|
|
|
-
|
-
|
-
|
-
|
-
|